Evaluation of CA-125 and other biochemical parameters in premenopausal and postmenopausal women with ovarian cancer: a hospital based study from Western Nepal

Thanpari, C; Yadav, Neelu; Takhelmayum, Roshan; Shrewastwa, Mukesh Kumar; Mittal, Rabindra Kumar; Thapa, Pradeep

doi:10.1016/s2222-1808(14)60713-1

Cited by 1 publication

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, in a low number of studies to determine the prognostic value of serum ADA levels in ovarian cancer, elevated serum ADA levels were described in patients with ovarian cancer [12,14] . In fact, this increase is reported to be in both premenepausal and postmeneposal ovarian cancer patients [30] .…”

Section: Discussionmentioning

confidence: 92%

“…This reduces the usability of CA 125, especially in the premenopausal period [10] . Chhunthang Thanpari et al [30] evaluated CA-125, ADA and other biochemical parameters in 43 premenopausal and 21 postmenopausal ovarian cancer patients found that serum CA 125 and ADA levels were significantly higher in both premenepausal and postmenepausal ovarian cancer patients than in the control group. Pragathi et al [12] reported that the threshold for ADA was 30 U/L, which is the upper limit of the range obtained for healthy controls.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adenosine deaminase (ADA) and cancer antigen 125 (CA 125) levels in patients with epithelial ovarian neoplasm

Taş¹

2018

Haydarpasa Numune Med J

View full text Add to dashboard Cite

Introduction: In this study, we aimed to determine serum adenosine deaminase (ADA) and cancer antigen 125 (CA 125) levels in patients with epithelial ovarian tumors. Methods: A total of 75 patients with 47 malignant and 28 benign epithelial ovarian tumors were included in this case-control study. On the morning of the operation, serum CA 125 and ADA levels were determined. Postoperative epithelial ovarian tumor patients were divided into two subgroups as benign and malignant histopathologically. We evaluated whether there was a correlation between tumor levels and serum CA-125 and ADA levels of subgroups and malignant patients. Results: Of 47 patients with malignant epithelial ovarian cancer, 20 of them had an early-stage (stage 1-2) and 27 of them had advanced-stage (stage 3-4) tumors. Serum CA-125 (26.38 vs 44.93, p<0.001) and ADA levels (29.91 vs 42. 82, p≤0.05) were significantly higher in malignant epithelial ovarian tumors than in benign epithelial ovarian tumors. There was no significant correlation between ADA levels. Discussion and Conclusion: This study showed that serum ADA levels in patients with epithelial ovarian cancer could be used as a biomarker in combination with other parameters for predicting malignancy in ovarian cancer. To validate these clinical data, large-scale studies of epithelial ovarian tumors are needed.

show abstract

Section: Discussionmentioning

confidence: 92%